Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost

Autor:	Maram Mohammed El Tabaa, Manar Mohammed El Tabaa
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	0301 basic medicine ACEI ACE inhibitors RAS Renin angiotensin system Aβ β-amyloid MERS Middle East Respiratory Syndrome VEGF Vascular endothelial growth factor ALI/ARDS Acute lung injury/Acute respiratory distress syndrome Bioinformatics Biochemistry 0302 clinical medicine MCP-1 Monocyte chemoattractant protein-1 NF-kB Nuclear factor kappa B Bradykinins NPs Natriuretic peptides MasR Mas receptor Medicine PPARs Peroxisome proliferator activator receptors BR Bradykinin receptor IL Interleukin Ang (1-7) Neprilysin COVID-19 Coronavirus disease 2019 GPCR G protein-coupled PNECs Pulmonary neuroendocrine cells CQ/HCQ Chloroquine/Hydroxychloroquine Endothelin-1 TGF-β1 Transforming growth factor- β1 BKs Bradykinins SERMs Selective estrogen receptor modulators Coronavirus disease Drug repositioning ET-1 Endothelin-1 030220 oncology & carcinogenesis NEPi Neprilysin inhibitors ARBs Angiotensin receptor blockers GRP AD Alzheimer's disease HO-1 Heme oxygenase-1 AT1R Angiotensin II receptor type 1 fMLP formyl Methionyl-meucyl-proline 2019-20 coronavirus outbreak MAPK/ERK Mitogen-activated protein kinases/ Extracellular signal-regulated kinases Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) GRP Gastrin-releasing peptide PLCb/IP3 Phospholipase C beta/inositol trisphosphate NO Nitric oxide Article SARS-CoV Severe acute respiratory syndrome coronavirus 03 medical and health sciences NEP Neprilysin Beneficial effects ComputingMethodologies_COMPUTERGRAPHICS Pharmacology NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) business.industry fungi eNOS endothelial Nitric oxide synthase TNF Tumor necrosis factor ACE Angiotensin-converting enzyme Nrf2 Nuclear factor erythroid 2–related factor 2 STZ Streptozotocin ECs Endothelial cells 030104 developmental biology fMLP GM-CSF Granulocyte-macrophage colony-stimulating factor NSAIDs Non steroidal anti-inflammatory drugs business Coronavirus Infections AT2R Angiotensin II receptor type 2 Ang Angiotensin ROS Reactive oxygen species
Zdroj:	Biochemical Pharmacology
ISSN:	1873-2968 0006-2952
Popis:	Graphical abstract COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3288262888c0c58d8afaae1b90afb12 http://europepmc.org/articles/PMC7250789 Zobrazit plný text záznamu Full Text from ScienceDirect